The $14 Billion Import Bill Africa’s Health Systems Cannot Afford
Africa spends an estimated $14 billion annually on imported pharmaceutical products — medicines that could, and should, be manufactured on the continent. The figure has become a rallying cry for a growing coalition of African governments, development finance institutions, and private investors who argue that Africa’s health sovereignty depends on building a domestic drug manufacturing base.
The COVID-19 pandemic exposed the flaw in Africa’s reliance on imported medicines with brutal clarity. When India restricted exports of active pharmaceutical ingredients (APIs) and finished doses in 2020 and 2021, African countries — with virtually no domestic manufacturing capacity — were left at the back of the queue for vaccines and essential medicines. The lesson has not been forgotten.
From Dependency to Production: A New Ambition
The post-pandemic period has seen an acceleration of initiatives aimed at building Africa’s pharmaceutical production capacity. Rwanda and Ghana have emerged as frontrunners, with new facilities under construction in Kigali and Accra. Kenya’s government has announced tax incentives for local pharmaceutical manufacturers as part of its economic stimulus programme. And Nigeria, Africa’s largest economy and most populous nation, has made local drug production a centrepiece of its health ministry’s five-year plan.
The African Development Bank (AfDB) has committed $2 billion in concessional financing for pharmaceutical infrastructure across the continent, with a focus on establishing regional manufacturing hubs that can serve multiple markets. The rationale is both economic and strategic: reducing the continent’s health dependency on external supply chains while creating jobs and building technical expertise.
The API Problem
The biggest bottleneck is not finished product manufacturing — it is the production of active pharmaceutical ingredients. The vast majority of Africa’s drug manufacturers currently import APIs from India and China, which means they remain dependent on the same external supply chains they are trying to escape. Building API production capacity requires significant capital investment, advanced technical expertise, and a reliable supply of precursor chemicals.
Ethiopia has made the most progress here, with a new API facility in Addis Ababa that supplies regional manufacturers. But the facility is small relative to continental demand, and scaling it requires sustained investment that many investors remain cautious about committing given the perceived regulatory and political risks.
Financing and Philanthropy Step In
With traditional development finance constrained and commercial bank lending to the sector limited, philanthropy has emerged as an important bridge. The Bill and Melinda Gates Foundation has backed several initiatives in this space, including partnerships with African pharmaceutical companies to develop generic formulations for HIV, malaria, and TB treatments that can be produced locally.
The Tony Blair Institute and the European Commission’s Team Europe initiative have also launched programmes to support regulatory harmonisation across African Union member states — a key requirement for pharmaceutical companies seeking to serve multiple markets without navigating a labyrinth of different national approval processes.
Regulatory Reform as a Prerequisite
Beyond financing, the biggest structural barrier to Africa’s pharmaceutical development is regulatory fragmentation. Each African country maintains its own medicines regulatory authority, with varying standards, approval timelines, and enforcement capacity. The African Medicines Agency (AMA), established by the African Union in 2021, was designed to address this — but the agency remains underfunded and politically contested, with several major economies yet to ratify its founding treaty.
Until regulatory harmonisation advances, African manufacturers face the same fragmentation challenge that has limited intra-African trade more broadly. A drug approved in Kenya cannot automatically be sold in Tanzania without a separate approval process — a duplication of cost and time that undermines the economics of regional scale.
The Path Ahead
Africa’s push for pharmaceutical sovereignty is ambitious but achievable. The continent has the market size, the demographic trajectory, and increasingly the institutional frameworks to support a domestic industry. What it lacks is the sustained capital commitment, the regulatory coherence, and the political will to treat pharmaceutical manufacturing as a strategic sector rather than merely a health policy footnote.
The next two years will be decisive. Several new facilities are scheduled to come online, and the African Union has set a target of 60% local production of essential medicines by 2030. Whether that target is met depends less on the ambition of the policy pronouncements and more on whether the financing and regulatory reforms keep pace with the infrastructure investments already underway.